Precigen Inc
(FRA:I5X)
€
0.8505
0.017 (2.04%)
Market Cap: 264.54 Mil
Enterprise Value: 252.32 Mil
PE Ratio: 0
PB Ratio: 5.71
GF Score: 45/100 
Precigen Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023 / 08:55PM GMT
Release Date Price:
€1.37
(+7.03%)
Jennifer M. Kim
Cantor Fitzgerald & Co., Research Division - Biopharma & Biotech Analyst
Our final fireside chat of the day. I'm Jennifer Kim, a biopharma and biotech analyst here at Cantor. And I'm looking forward to hosting Helen Sabzevari, President and CEO of Precigen. Helen, thanks for joining us.
Helen Sabzevari
Precigen, Inc. - President, CEO & Director
Thank you for having us.
Questions & Answers
Jennifer M. Kim
Cantor Fitzgerald & Co., Research Division - Biopharma & Biotech Analyst
Okay. Maybe we can start. Could you give a brief introduction of yourself and Precigen?
Helen Sabzevari;
Precigen, Inc. - President, CEO & Director
Sure. I'm Helen Sabzevari. As you mentioned, I'm the CEO and President of Precigen. And Precigen is a biotech company that focuses on cell and gene therapy that it specifically addresses the Precigen medicine by activating the immune system in various fashion and different indications.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers